Legal Status This site displays a prototype of a “Web 2.0” version of the daily
Federal Register. It is not an official legal edition of the Federal
Register, and does not replace the official print version or the official
electronic version on GPO’s govinfo.gov.

The documents posted on this site are XML renditions of published Federal
Register documents. Each document posted on the site includes a link to the
corresponding official PDF file on govinfo.gov. This prototype edition of the
daily Federal Register on FederalRegister.gov will remain an unofficial
informational resource until the Administrative Committee of the Federal
Register (ACFR) issues a regulation granting it official legal status.
For complete information about, and access to, our official publications
and services, go to About the Federal Register on NARA's archives.gov.

The OFR/GPO partnership is committed to presenting accurate and reliable
regulatory information on FederalRegister.gov with the objective of
establishing the XML-based Federal Register as an ACFR-sanctioned
publication in the future. While every effort has been made to ensure that
the material on FederalRegister.gov is accurately displayed, consistent with
the official SGML-based PDF version on govinfo.gov, those relying on it for
legal research should verify their results against an official edition of
the Federal Register. Until the ACFR grants it official status, the XML
rendition of the daily Federal Register on FederalRegister.gov does not
provide legal notice to the public or judicial notice to the courts.

Legal Status

Notice

You may be interested in this older document that published on 12/09/2025 with action 'Notice.' View Document

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Mammography Standards Quality Act Requirements

A Notice by the Food and Drug Administration on 03/13/2026

• 1.

1.
This document has a comment period that ends in 30 days.
(04/13/2026) Submit a public comment

Thank you for taking the time to create a comment. Your input is important.

Once you have filled in the required fields below you can preview and/or submit your comment to the Health and Human Services Department for review. All comments are considered public and will be posted online once the Health and Human Services Department has reviewed them.

You can view alternative ways to comment or you may also comment via Regulations.gov at https://www.regulations.gov/commenton/FDA-2025-N-4942-0002.

It appears that you have attempted to comment on this document before
so we've restored your progress.
Start over.
1.
2. Comment * What is your comment about? Upload File(s) Note: You can attach your comment as a file and/or attach supporting
documents to your comment. Attachment Requirements.

Email this will NOT be posted on regulations.gov

Opt to receive email confirmation of submission and tracking number? Tell us about yourself! I am... * An Individual An Organization Anonymous First Name * Last Name * City Region State Alabama Alaska American Samoa Arizona Arkansas California Colorado Connecticut Delaware District of Columbia Florida Georgia Guam Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Puerto Rico Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virgin Islands Virginia Washington West Virginia Wisconsin Wyoming Zip Country Afghanistan Åland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Côte d'Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People's Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Macedonia, the Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestine, State of Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Réunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Viet Nam Virgin Islands, British Virgin Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Phone Organization Type * Company Organization Federal State Local Tribal Regional Foreign U.S. House of Representatives U.S. Senate Organization Name * You are filing a document into an official docket. Any personal
information included in your comment text and/or uploaded
attachment(s) may be publicly viewable on the web. I read and understand the statement above.

2. Preview Comment Please review the Regulations.gov privacy notice and user notice.
3. Document Details Published Content - Document Details Agencies Department of Health and Human Services Food and Drug Administration Agency/Docket Number Docket No. FDA-2025-N-4942 Document Citation 91 FR 12427 Document Number 2026-04939 Document Type Notice Pages 12427-12429 (3 pages) Publication Date 03/13/2026 Published Content - Document Details

• PDF Official Content
  • View printed version (PDF) Official Content
• Document Details Published Content - Document Details Agencies Department of Health and Human Services Food and Drug Administration Agency/Docket Number Docket No. FDA-2025-N-4942 Document Citation 91 FR 12427 Document Number 2026-04939 Document Type Notice Pages 12427-12429 (3 pages) Publication Date 03/13/2026 Published Content - Document Details
• Document Dates Published Content - Document Dates Comments Close 04/13/2026 Dates Text Submit written comments (including recommendations) on the collection of information by April 13, 2026. Published Content - Document Dates

• Table of Contents Enhanced Content - Table of Contents This table of contents is a navigational tool, processed from the
  headings within the legal text of Federal Register documents.
  This repetition of headings to form internal navigation links
  has no substantive legal effect.

  • AGENCY:
  • ACTION:
  • SUMMARY:
  • DATES:
  • ADDRESSES:
  • FOR FURTHER INFORMATION CONTACT:
  • SUPPLEMENTARY INFORMATION:
  • Mammography Quality Standards Act Requirements— 21 CFR Part 900
  • OMB Control Number 0910-0309—Extension Enhanced Content - Table of Contents

• Related Documents Enhanced Content - Related Documents FederalRegister.gov uses the agency dockets published with the document to display related documents.

| Docket No. FDA-2025-N-4942
(2 Documents) | | | |
| --- | | | |
| Date | | Action | Title |
| | 2026-03-13 | Notice. | Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Mammography Standards Quality Act Requirements |
| | 2025-12-09 | Notice. | Agency Information Collection Activities; Proposed Collection; Comment Request; Mammography Standards Quality Act Requirements |

Enhanced Content - Related Documents

• Public Comments Enhanced Content - Public Comments Comments are being accepted - Submit a public comment.

Enhanced Content - Public Comments
- Regulations.gov Data Enhanced Content - Regulations.gov Data

FederalRegister.gov retrieves relevant information about this document
from Regulations.gov to provide users with additional context. This
information is not part of the official Federal Register document.

Agency Information Collection Activities; Proposed Collection; Comment Request; Mammography Standards Quality Act Requirements

Comment Due Date 04/13/2026 Docket ID FDA-2025-N-4942 Supporting Documents No supporting documents available Enhanced Content - Regulations.gov Data

- Sharing Enhanced Content - Sharing Shorter Document URL https://www.federalregister.gov/d/2026-04939 Email Email this document to a friend Enhanced Content - Sharing

• Print Enhanced Content - Print
  • Print this document Enhanced Content - Print
• Document Statistics Enhanced Content - Document Statistics Document page views are updated periodically throughout the day and are cumulative counts for this document. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.

Page views 72
as of
03/14/2026 at 2:15 pm EDT Enhanced Content - Document Statistics
- Other Formats Enhanced Content - Other Formats This document is also available in the following formats:

JSON Normalized attributes and metadata XML Original full text XML MODS Government Publishing Office metadata More information and documentation can be found in our developer tools pages.

Enhanced Content - Other Formats
- Public Inspection Public Inspection This PDF is FR Doc. 2026-04939 as it appeared on Public Inspection on
03/12/2026 at 8:45 am.

It was viewed
35
times while on Public Inspection.

If you are using public inspection listings for legal research, you
should verify the contents of the documents against a final, official
edition of the Federal Register. Only official editions of the
Federal Register provide legal notice of publication to the public and judicial notice
to the courts under 44 U.S.C. 1503 & 1507. Learn more here.

Public Inspection
Published Document: 2026-04939 (91 FR 12427) This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Document Headings Document headings vary by document type but may contain
the following:

1. the agency or agencies that issued and signed a document
2. the number of the CFR title and the number of each part the document amends, proposes to amend, or is directly related to
3. the agency docket number / agency internal file number
4. the RIN which identifies each regulatory action listed in the Unified Agenda of Federal Regulatory and Deregulatory Actions See the Document Drafting Handbook for more details.

Department of Health and Human Services

Food and Drug Administration

1. [Docket No. FDA-2025-N-4942]

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES:

Submit written comments (including recommendations) on the collection of information by April 13, 2026.

ADDRESSES:

To ensure that comments on the information collection are received, OMB recommends that written comments be submitted to https://www.reginfo.gov/​public/​do/​PRAMain. Find this particular information collection by selecting “Currently under Review—Open for Public Comments” or by using the search function. The OMB control number for this information collection is 0910-0309.

FOR FURTHER INFORMATION CONTACT:

Amber Barrett, Office of Operations, Food and Drug Administration, Three White Flint North, 10A-12M, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-8867, PRAStaff@fda.hhs.gov.

SUPPLEMENTARY INFORMATION:

In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

Mammography Quality Standards Act Requirements— 21 CFR Part 900

OMB Control Number 0910-0309—Extension

The Mammography Quality Standards Act (Pub. L. 102-539) requires the establishment of a Federal certification and inspection program for mammography facilities; standards for accreditation and certification bodies for mammography facilities; and standards for mammography equipment, personnel, and practices, including quality assurance. Implementing regulations are found in part 900 (21 CFR part 900). The regulations are intended to assure safe, reliable, and accurate mammography on a nationwide level. Under the regulations, as a first step in becoming certified, mammography facilities must become accredited by an FDA-approved accreditation body (AB). This requires undergoing a review of their clinical images and providing the AB with information showing that they meet the equipment, personnel, quality assurance, and quality control standards, and have a medical reporting and recordkeeping program, a medical outcomes audit program, and a consumer complaint mechanism. On the basis of this accreditation, facilities are then certified by FDA or an FDA-approved State certification agency and must prominently display their certificate. These actions are taken to ensure safe, accurate, and reliable mammography on a nationwide basis.

FDA meets with its National Mammography Quality Assurance Advisory Committee (NMQAAC) for the purposes of advising FDA's mammography program on advances in mammography technology and procedures and on appropriate quality standards for mammography facilities. NMQAAC is made up of representatives of the mammography community, consumer and industry groups, and government. The meetings are open to the public and time is allotted for public statements on issues of concern in the mammography field. The chairperson may also call upon attendees to contribute to the committee discussions.

FDA also regularly meets or holds teleconferences with its approved accreditation bodies and State certification agencies to discuss issues of mutual concern. We also engage with the Conference of State Radiation Program Directors (CRCPD), a professional organization of State agencies concerned with radiation protection. The CRCPD has established a standing Mammography Committee, which meets with FDA mammography staff at least once a year.

Finally, in recent years, FDA mammography staff have met several times with representatives of manufacturers working on the new applications of digital technology in mammography to resolve problems preventing the making of that technology generally available. FDA mammography staff have also worked with representatives of the manufacturers to develop quality assurance manuals for full field digital mammography units.

In the Federal Register of December 9, 2025 (90 FR 57070), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received.

FDA estimates the burden of this collection of information as follows:

| Activity/21 CFR section/FDA form No. | Number of
respondents | Number of
responses per
respondent | Total
annual
responses | Average burden per response | Total hours |
| --- | --- | --- | --- | --- | --- |
| PART 900, MAMMOGRAPHY | | | | | |
| Subpart A, Accreditation | | | | | |
| Notification of intent to become an AB—900.3(b)(1) | 0.33 | 1 | 0.33 | 1 | 1 |
| Application for approval as an AB; full 2 —900.3(b)(3) | 0.33 | 1 | 0.33 | 320 | 106 |
| Application for approval as an AB; limited 3 —900.3(b)(3) | 5 | 1 | 5 | 30 | 150 |
| AB renewal of approval—900.3(c) | 1 | 1 | 1 | 15 | 15 |
| AB application deficiencies—900.3(d)(2) | 0.1 | 1 | 0.1 | 30 | 3 |
| AB resubmission of denied applications—900.3(d)(5) | 0.1 | 1 | 0.1 | 30 | 3 |
| Letter of intent to relinquish accreditation authority—900.3(e) | 0.1 | 1 | 0.1 | 1 | 1 |
| Summary report describing all facility assessments—900.4(f) | 338 | 1 | 338 | 7 | 2,366 |
| ( printed page 12428) | | | | | |
| AB reporting to FDA; facility 4 —900.4(h) | 8,931 | 1 | 8,931 | 1 | 8,931 |
| AB reporting to FDA; AB 5 —900.4(h) | 5 | 1 | 5 | 10 | 50 |
| AB financial records—900.4(i)(2) | 1 | 1 | 1 | 16 | 16 |
| Former AB new application—900.6(c)(1) | 0.1 | 1 | 0.1 | 60 | 6 |
| Total Subpart A | | | | | 11,648 |
| Subpart B, Quality and Standards Certification | | | | | |
| Reconsideration of accreditation following appeal—900.15(d)(3)(ii) | 1 | 1 | 1 | 2 | 2 |
| Application for alternative standard—900.18(c) | 2 | 1 | 2 | 2 | 4 |
| Alternative standard amendment—900.18(e) | 10 | 1 | 10 | 1 | 10 |
| Total Subpart B | | | | | 16 |
| Subpart C, States as Certifiers | | | | | |
| Certification agency application—900.21(b) | 0.33 | 1 | 0.33 | 320 | 106 |
| Certification agency application deficiencies—900.21(c)(2) | 0.1 | 1 | 0.1 | 30 | 3 |
| Certification electronic data transmission—900.22(h) | 5 | 200 | 1000 | 0.083 (5 minutes) | 83 |
| Changes to standards—900.22(i) | 2 | 1 | 2 | 30 | 60 |
| Certification agency minor deficiencies—900.24(b) | 1 | 1 | 1 | 30 | 30 |
| Appeal of adverse action taken by FDA—900.25(a) | 0.2 | 1 | 0.2 | 16 | 3 |
| Total Subpart C | | | | | 285 |
| Inspection fee exemption—FDA Form 3422 | 355 | 1 | 355 | 0.25 (15 minutes) | 89 |
| Total | | | | | 12,038 |
| 1 Numbers have been rounded. | | | | | |
| 2 One-time burden. | | | | | |
| 3 Refers to accreditation bodies applying to accredit specific full-field digital mammography units. | | | | | |
| 4 Refers to the facility component of the burden for this requirement. | | | | | |
| 5 Refers to the AB component of the burden for this requirement. | | | | | |

| Activity/21 CFR section | Number of
recordkeepers | Number of
records per
recordkeeper | Total
annual
records | Average burden per recordkeeping | Total hours 1 |
| --- | --- | --- | --- | --- | --- |
| Part 900, MAMMOGRAPHY | | | | | |
| Subpart A, Accreditation | | | | | |
| AB transfer of facility records—900.3(f)(1) | 0.1 | 1 | 0.1 | 1 | 1 |
| Consumer complaints system; AB—900.4(g) | 5 | 1 | 5 | 1 | 5 |
| Total Subpart A | | | | | 6 |
| Subpart B, Quality and Standards Certification | | | | | |
| Documentation of interpreting physician initial requirements—900.12(a)(1)(i)(B)(2) | 89 | 1 | 89 | 8 | 712 |
| Documentation of interpreting physician personnel requirements—900.12(a)(4) | 8,931 | 4 | 35,724 | 1 | 35,724 |
| Permanent medical record—900.12(c)(4) | 8,931 | 1 | 8,931 | 1 | 8,931 |
| Procedures for cleaning equipment—900.12(e)(13) | 8,931 | 52 | 464,412 | 0.083 (5 minutes) | 38,546 |
| Audit program—900.12(f) | 8,931 | 1 | 8,931 | 16 | 142,896 |
| Consumer complaints system; facility—900.12(h)(2) | 8,931 | 2 | 17,862 | 1 | 17,862 |
| Total Subpart B | | | | | 244,671 |
| Subpart C, States as Certifiers | | | | | |
| Certification agency conflict of interest—900.22(a) | 4 | 1 | 4 | 1 | 4 |
| Processes for suspension and revocation of certificates—900.22(d) | 4 | 1 | 4 | 1 | 4 |
| Processes for appeals—900.22(e) | 4 | 1 | 4 | 1 | 4 |
| Processes for additional mammography review—900.22(f) | 4 | 1 | 4 | 1 | 4 |
| Processes for patient notifications—900.22(g) | 3 | 1 | 3 | 1 | 3 |
| Evaluation of certification agency—900.23 | 4 | 1 | 4 | 20 | 80 |
| Appeals—900.25(b) | 4 | 1 | 4 | 1 | 4 |
| Total Subpart C | | | | | 103 |
| Total | | | | | 244,774 |
| 1 Total hours have been rounded. | | | | | |
( printed page 12429)
| Activity/21 CFR section | Number of
respondents | Number of
disclosures
per
respondent | Total annual
disclosures | Average burden per disclosure | Total hours 1 |
| --- | --- | --- | --- | --- | --- |
| PART 900, MAMMOGRAPHY | | | | | |
| Subpart A, Accreditation | | | | | |
| Notification of facilities that AB relinquishes its accreditation—900.3(f)(2) | 0.1 | 1 | 0.1 | 200 | 20 |
| Clinical images; facility 2 —900.4(c), 900.11(b)(1), and 900.11(b)(2) | 2,955 | 1 | 2,955 | 1.44 | 4,255 |
| Clinical images; AB 3 —900.4(c) | 5 | 1 | 5 | 416 | 2,080 |
| Phantom images; facility 2 —900.4(d), 900.11(b)(1), and 900.11(b)(2) | 2,955 | 1 | 2,955 | 0.72 (43 minutes) | 2,128 |
| Phantom images; AB 3 —900.4(d) | 5 | 1 | 5 | 208 | 1,040 |
| Annual equipment evaluation and survey; facility 2 —900.4(e), 900.11(b)(1), and 900.11(b)(2) | 8,931 | 1 | 8,931 | 1 | 8,931 |
| Annual equipment evaluation and survey; AB 3 —900.4(e) | 5 | 1 | 5 | 1,730 | 8,650 |
| Total Subpart A | | | | | 27,104 |
| Subpart B, Quality Standards and Certification | | | | | |
| Provisional mammography facility certificate extension application—900.11(b)(3) | 2 | 1 | 2 | 0.5 (30 minutes) | 1 |
| Mammography facility certificate reinstatement application—900.11(c) | 288 | 1 | 288 | 5 | 1,440 |
| Provision of personnel records to IPs—900.12(a)(4) | 615 | 1 | 615 | 0.08 (5 minutes) | 49 |
| Transfer of personnel records by closing facilities—900.12(a)(4) | 190 | 1 | 190 | 5 | 950 |
| New assessment categories and breast density reporting in mammography report (one-time burden)—900.12(c)(1)(iv) to (vi) | 8,931 | 1 | 8,931 | 23 | 205,413 |
| Lay summary of examination—900.12(c)(2) | 8,931 | 5,085 | 45,414,135 | 0.083 (5 minutes) | 3,769,373 |
| Breast density reporting in lay summary (one-time burden)—900.12(c)(2) | 8,931 | 1 | 8,931 | 11 | 98,241 |
| Lay summary of examination; patient refusal 4 —900.12(c)(2) | 89 | 1 | 89 | 0.5 (30 minutes) | 45 |
| Transfer/provision of copies of mammograms and records upon patient's request—900.12(c)(4)(ii) and (iii) | 8,931 | 520 | 4,644,120 | 0.08 (5 minutes) | 371,530 |
| Facility closure; notification and records access—900.12(c)(4)(v) | 190 | 1 | 190 | 32 | 6,080 |
| Report of unresolved serious complaints—900.12(h)(4) | 20 | 1 | 20 | 1 | 20 |
| Information regarding compromised quality; facility 2 —900.12(j)(1) | 20 | 1 | 20 | 200 | 4,000 |
| Information regarding compromised quality; AB 3 —900.12(j)(1) | 20 | 1 | 20 | 320 | 6,400 |
| Patient notification of serious risk—900.12(j)(2) | 7 | 1 | 7 | 100 | 700 |
| Reconsideration of accreditation—900.15(c) | 5 | 1 | 5 | 2 | 10 |
| Total Subpart B | | | | | 4,464,252 |
| Subpart C, States as Certifiers | | | | | |
| Notification of requirement to correct major deficiencies—900.24(a) | 0.4 | 1 | 0.4 | 200 | 80 |
| Notification of loss of approval; major deficiencies—900.24(a)(2) | 0.15 | 1 | 0.15 | 100 | 15 |
| Notification of probationary status—900.24(b)(1) | 0.3 | 1 | 0.3 | 200 | 60 |
| Notification of loss of approval; minor deficiencies—900.24(b)(3) | 0.15 | 1 | 0.15 | 100 | 15 |
| Total Subpart C | | | | | 170 |
| Total | | | | | 4,491,526 |
| 1 Total hours have been rounded. | | | | | |
| 2 Refers to the facility component of the burden for this requirement. | | | | | |
| 3 Refers to the AB component of the burden for this requirement. | | | | | |
| 4 Refers to the situation where a patient specifically does not want to receive the lay summary of her exam. | | | | | |
Our estimated burden for the information collection reflects an overall decrease of 4,225,729 hours and a corresponding decrease of 321,202 responses. We attribute this adjustment due to the number of certified mammography facilities. The estimated number of respondents in the tables are based on the number (8,931) of certified mammography facilities as of October 1, 2024. Title 21 CFR part 900 Mammography, as amended, includes various reporting, recordkeeping, and third-party disclosure activities. In addition, there was a decrease in state certifiers from 5 to 4—Illinois, Iowa, South Carolina, and Texas.

Grace R. Graham,

Deputy Commissioner for Policy, Legislation, and International Affairs.

[FR Doc. 2026-04939 Filed 3-12-26; 8:45 am]

BILLING CODE 4164-01-P

Published Document: 2026-04939 (91 FR 12427)